litlas
Log inCreate account

Douglas B. Johnson

Active 2013–2025

267
Papers
49,243
Citations
103
h-index
249
i10-index

Citations

Citations per year for Douglas B. Johnson1945: 1 citations1974: 1 citations2001: 1 citations2003: 3 citations2009: 2 citations2010: 1 citations2012: 4 citations2013: 3 citations2014: 46 citations2015: 108 citations2016: 193 citations2017: 464 citations2018: 620 citations2019: 1,965 citations2020: 3,046 citations2021: 3,182 citations2022: 2,951 citations2023: 2,359 citations2024: 4,166 citations2025: 1,997 citations2026: 42 citations1946–1973: no citations, so these years are not shown1975–2000: no citations, so these years are not shown2002: no citations, so this year is not shown2004–2008: no citations, so these years are not shown2011: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 5,888 citing papers, 25.2% of this breakdownChina: 3,679 citing papers, 15.8% of this breakdownItaly: 1,270 citing papers, 5.4% of this breakdownUnited Kingdom: 1,173 citing papers, 5% of this breakdownGermany: 1,140 citing papers, 4.9% of this breakdownFrance: 1,033 citing papers, 4.4% of this breakdownAustralia: 798 citing papers, 3.4% of this breakdownCanada: 642 citing papers, 2.8% of this breakdownSpain: 630 citing papers, 2.7% of this breakdownNetherlands: 618 citing papers, 2.6% of this breakdownJapan: 616 citing papers, 2.6% of this breakdownSwitzerland: 554 citing papers, 2.4% of this breakdown
0%25.2%Other 22.8%

Institutions

Fields

  • Medicine66.7%
  • Biochemistry, Genetics and Molecular Biology19.1%
  • Immunology and Microbiology9%
  • Engineering1.6%
  • Computer Science1.4%
  • Neuroscience0.4%
  • Other1.8%

Topics

  • Cancer Immunotherapy and Biomarkers15.6%
  • Immunotherapy and Immune Responses5.6%
  • CAR-T cell therapy research4.4%
  • Melanoma and MAPK Pathways3.5%
  • Immune Cell Function and Interaction2.8%
  • Cutaneous Melanoma Detection and Management2.6%
  • Other65.5%

Coauthors

All papers

Open in search
  1. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors

    Authors: Daniel Wang, Joe‐Elie Salem, Justine V. Cohen, Sunandana Chandra, Christian Menzer, Fei Ye, Shilin Zhao, Satya Das, Kathryn E. Beckermann, Lisa Ha, W. Kimryn Rathmell, Kristin Kathleen Ancell, Justin M. Balko, Caitlin Bowman, Elizabeth J. Davis, David D. Chism, Leora Horn, Georgina V. Long, Matteo S. Carlino, Bénédicte Lebrun‐Vignes, Zeynep Eroglu, Jessica C. Hassel, Alexander M. Menzies, Jeffrey A. Sosman, Ryan J. Sullivan, Javid J. Moslehi, Douglas B. Johnson - JAMA Oncology 2018 cited by 2,609

  2. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

    Authors: Willy Hugo, Jesse M. Zaretsky, Lu ming Sun, Chunying Song, Blanca Homet Moreno, Siwen Hu‐Lieskovan, Beata Berent-Maoz, Jia Pang, Bartosz Chmielowski, Grace Cherry, Elizabeth Seja, Shirley H. Lomeli, Xiangju Kong, Mark C. Kelley, Jeffrey A. Sosman, Douglas B. Johnson, Antoni Ribas, Roger S. Lo - Cell 2016 cited by 3,569

  3. Assessing the Accuracy and Reliability of AI-Generated Medical Responses: An Evaluation of the Chat-GPT Model

    Authors: Douglas B. Johnson, Rachel Goodman, James R. Patrinely, Cosby A. Stone, Eli E. Zimmerman, Rebecca Donald, Sam S. Chang, Sean T. Berkowitz, Avni P. Finn, Eiman Jahangir, Elizabeth Scoville, Tyler Reese, Debra L. Friedman, Julie A. Bastarache, Yuri F. van der Heijden, J. J. Wright, Nick Carter, Matthew R. Alexander, Jennifer H. Choe, Cody A. Chastain, John A. Zic, Sara N. Horst, Isik Turker, Rajiv Agarwal, Evan C. Osmundson, Kamran Idrees, Colleen M. Kiernan, Chandrasekhar Padmanabhan, Christina E. Bailey, Cameron Schlegel, Lola B. Chambless, Mike Gibson, Travis Osterman, Lee Wheless - 2023 cited by 599

  4. Immune-checkpoint inhibitors: long-term implications of toxicity

    Authors: Douglas B. Johnson, Caroline A. Nebhan, Javid J. Moslehi, Justin M. Balko - Nature Reviews Clinical Oncology 2022 cited by 913

  5. Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data

    Authors: Francesca Finotello, Clemens Mayer, Christina Plattner, Gerhard Laschober, Dietmar Rieder, Hubert Hackl, Anne Krogsdam, Zuzana Loncová, Wilfried Posch, Doris Wilflingseder, Sieghart Sopper, Marieke E. Ijsselsteijn, Thomas P. Brouwer, Douglas B. Johnson, Yaomin Xu, Yu Wang, Melinda E. Sanders, Mónica V. Estrada, Paula I. González-Ericsson, Pornpimol Charoentong, Justin M. Balko, Noel F.C.C. de Miranda, Zlatko Trajanoski - Genome Medicine 2019 cited by 1,681

  6. Fulminant Myocarditis with Combination Immune Checkpoint Blockade

    Authors: Douglas B. Johnson, Justin M. Balko, Margaret Compton, Spyridon Chalkias, Joshua Gorham, Yaomin Xu, Mellissa Hicks, Igor Puzanov, Matthew R. Alexander, Tyler Bloomer, Jason R. Becker, David Slosky, Elizabeth J. Phillips, Mark A. Pilkinton, Laura Deeanne Craig-Owens, Nina Kola, Gregory E. Plautz, Daniel S. Reshef, Jonathan S. Deutsch, Raquel P. Deering, Benjamin A. Olenchock, Andrew H. Lichtman, Dan M. Roden, Christine E. Seidman, Igor J. Koralnik, Jonathan G. Seidman, Robert Hoffman, Janis M. Taube, Luis A. Díaz, Robert A. Anders, Jeffrey A. Sosman, Javid J. Moslehi - New England Journal of Medicine 2016 cited by 2,276

  7. Accuracy and Reliability of Chatbot Responses to Physician Questions

    Authors: Rachel Goodman, James R. Patrinely, Cosby A. Stone, Eli E. Zimmerman, Rebecca R. Donald, Sam S. Chang, Sean T. Berkowitz, Avni P. Finn, Eiman Jahangir, Elizabeth Scoville, Tyler Reese, Debra L. Friedman, Julie A. Bastarache, Yuri F. van der Heijden, J. J. Wright, Feifei Ye, Nick Carter, Matthew R. Alexander, Jennifer H. Choe, Cody A. Chastain, John A. Zic, Sara Horst, Isik Turker, Rajiv Agarwal, Evan C. Osmundson, Kamran Idrees, Colleen M. Kiernan, Chandrasekhar Padmanabhan, Christina E. Bailey, Cameron Schlegel, Lola B. Chambless, Michael K. Gibson, Travis Osterman, Lee Wheless, Douglas B. Johnson - JAMA Network Open 2023 cited by 445

  8. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

    Authors: Julie R. Brahmer, Hamzah Abu‐Sbeih, Paolo A. Ascierto, Jill Brufsky, Laura C. Cappelli, Frank B. Cortazar, David E. Gerber, Lamya Hamad, Eric Hansen, Douglas B. Johnson, Mario E. Lacouture, Gregory A. Masters, Jarushka Naidoo, Michele Nanni, Miguel‐Angel Perales, Igor Puzanov, Bianca Santomasso, Satish Shanbhag, Rajeev Sharma, Dimitra Skondra, Jeffrey A. Sosman, Michelle Turner, Marc S. Ernstoff - Journal for ImmunoTherapy of Cancer 2021 cited by 826

  9. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors

    Authors: Satya Das, Douglas B. Johnson - Journal for ImmunoTherapy of Cancer 2019 cited by 1,145

  10. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

    Authors: Joe‐Elie Salem, Ali Manouchehri, Melissa Moey, Bénédicte Lebrun‐Vignes, Lisa Bastarache, Alexandre Pariente, Aurélien Gobert, Jean‐Philippe Spano, Justin M. Balko, Marc P. Bonaca, Dan M. Roden, Douglas B. Johnson, Javid J. Moslehi - The Lancet Oncology 2018 cited by 1,209

  11. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy

    Authors: Daniel Shae, Kyle W. Becker, Plamen P. Christov, Dong Soo Yun, Abigail K. R. Lytton‐Jean, Sema Sevimli, Manuel Ascano, Mark C. Kelley, Douglas B. Johnson, Justin M. Balko, John T. Wilson - Nature Nanotechnology 2019 cited by 657

  12. T cells specific for α-myosin drive immunotherapy-related myocarditis

    Authors: Margaret L. Axelrod, Wouter C. Meijers, Elles M. Screever, Juan Qin, Mary Grace Carroll, Xiaopeng Sun, Elie Tannous, Yueli Zhang, Ayaka Sugiura, Brandie C. Taylor, Ann Hanna, Shaoyi Zhang, Kaushik Amancherla, Warren Tai, J. J. Wright, Spencer C. Wei, Susan R. Opalenik, Abigail Toren, Jeffrey C. Rathmell, P. Brent Ferrell, Elizabeth J. Phillips, S. Mallal, Douglas B. Johnson, James P. Allison, Javid J. Moslehi, Justin M. Balko - Nature 2022 cited by 321

  13. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis

    Authors: Javid J. Moslehi, Joe‐Elie Salem, Jeffrey A. Sosman, Bénédicte Lebrun‐Vignes, Douglas B. Johnson - The Lancet 2018 cited by 914

  14. Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade

    Authors: Steve Lu, Julie E. Stein, David L. Rimm, Daphne W. Wang, Michael A. Bell, Douglas B. Johnson, Jeffrey A. Sosman, Kurt A. Schalper, Robert A. Anders, Hao Wang, Clifford Hoyt, Drew M. Pardoll, Ludmila Danilova, Janis M. Taube - JAMA Oncology 2019 cited by 622

  15. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors

    Authors: Shona Hendry, Roberto Salgado, Thomas Gevaert, Prudence A. Russell, Tom John, Bibhusal Thapa, Michael Christie, Koen Van de Vijver, Mónica V. Estrada, Paula I. González-Ericsson, Melinda Sanders, Benjamin Solomon, Cinzia Solinas, Gert G. G. M. Van den Eynden, Yves Allory, Matthias Preusser, Johannes A. Hainfellner, Giancarlo Pruneri, Andrea Vingiani, Sandra Demaria, Fraser Symmans, Paolo Nucíforo, Laura Comerma, E. Aubrey Thompson, Sunil R. Lakhani, Seong-Rim Kim, Stuart J. Schnitt, Cécile Colpaert, Christos Sotiriou, Stefan Scherer, Michail Ignatiadis, Sunil Badve, Robert H. Pierce, Giuseppe Viale, Nicolas Sirtaine, Frédérique Penault‐Llorca, Tomohagu Sugie, Susan Fineberg, Soonmyung Paik, Ashok Srinivasan, Andrea L. Richardson, Yihong Wang, Ewa Chmielik, Jane Brock, Douglas B. Johnson, Justin M. Balko, Stephan Wienert, Veerle Bossuyt, Stefan Michiels, Nils Ternès, Nicole Burchardi, Stephen J. Luen, Peter Savas, Frederick Klauschen, Peter H. Watson, Brad H. Nelson, Carmen Criscitiello, Sandra A. O’Toole, Denis Larsimont, Roland de Wind, Giuseppe Curigliano, Fabrice André, Magali Lacroix‐Triki, Marc J. van de Vijver, Federico Rojo, Giuseppe Floris, Shahinaz Bedri, Joseph A. Sparano, David L. Rimm, Torsten O. Nielsen, Zuzana Kos, Stephen M. Hewitt, Baljit Singh, Gelareh Farshid, Sibylle Loibl, Kimberly H. Allison, Nadine Tung, Sylvia Adams, Karen Willard‐Gallo, Hugo M. Horlings, Leena Gandhi, André Moreira, Fred R. Hirsch, Maria Vittoria Dieci, María Urbanowicz, Iva Brčić, Konstanty Korski, Fabien Gaire, Hartmut Koeppen, Amy Lo, Jennifer M. Giltnane, Marlon C. Rebelatto, Keith E. Steele, Jiping Zha, Kenneth Emancipator, Jonathan Juco, Carsten Denkert, Jorge S. Reis‐Filho, Sherene Loi, Stephen B. Fox - Advances in Anatomic Pathology 2017 cited by 799

  16. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

    Authors: Douglas B. Johnson, Mónica V. Estrada, Roberto Salgado, Violeta Sánchez, Deon B. Doxie, Susan R. Opalenik, Anna E. Vilgelm, Emily Feld, Adam S. Johnson, Allison R. Greenplate, Melinda E. Sanders, Christine M. Lovly, Dennie T. Frederick, Mark C. Kelley, Ann Richmond, Jonathan M. Irish, Yu Shyr, Ryan J. Sullivan, Igor Puzanov, Jeffrey A. Sosman, Justin M. Balko - Nature Communications 2016 cited by 572

  17. Biological Consequences of MHC-II Expression by Tumor Cells in Cancer

    Authors: Margaret L. Axelrod, Rebecca S. Cook, Douglas B. Johnson, Justin M. Balko - Clinical Cancer Research 2018 cited by 496

  18. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

    Authors: Ari M. Vanderwalde, Shay Bellasea, Kari Kendra, Nikhil I. Khushalani, Katie M. Campbell, Philip O. Scumpia, Lawrence F. Kuklinski, Frances A. Collichio, Jeffrey A. Sosman, Alexandra P. Ikeguchi, Adrienne I. Victor, Thach‐Giao Truong, Bartosz Chmielowski, David C. Portnoy, Yuanbin Chen, Kim Margolin, Charles Bane, Constantin A Dasanu, Douglas B. Johnson, Zeynep Eroglu, Sunandana Chandra, Egmidio Medina, Cynthia R. Gonzalez, Ignacio Baselga-Carretero, Agustin Vega-Crespo, Ivan Perez Garcilazo, Elad Sharon, Siwen Hu‐Lieskovan, Sapna P. Patel, Kenneth F. Grossmann, James Moon, Michael C. Wu, Antoni Ribas - Nature Medicine 2023 cited by 167

  19. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

    Authors: Catherine S. Grasso, Jennifer Tsoi, Mykola Onyshchenko, Gabriel Abril-Rodríguez, Petra Ross‐Macdonald, Megan Wind‐Rotolo, Ameya S. Champhekar, Egmidio Medina, Davis Y. Torrejon, Daniel Sanghoon Shin, Phuong Tran, Yeon Joo Kim, Cristina Puig-Saus, Katie M. Campbell, Agustin Vega-Crespo, Michael J. Quist, Christophe Martignier, Jason J. Luke, Jedd D. Wolchok, Douglas B. Johnson, Bartosz Chmielowski, F. Stephen Hodi, Shailender Bhatia, William Sharfman, Walter J. Urba, Craig L. Slingluff, Adi Diab, John B.A.G. Haanen, Salvador Martín‐Algarra, Drew M. Pardoll, Valsamo Anagnostou, Suzanne L. Topalian, Victor E. Velculescu, Daniel E. Speiser, Anusha Kalbasi, Antoni Ribas - Cancer Cell 2020 cited by 383

  20. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

    Authors: Jennifer L. McQuade, Carrie R. Daniel, Kenneth R. Hess, Carmen Mak, Daniel Wang, Rajat R Rai, John Park, Lauren E. Haydu, Christine N. Spencer, Matthew Wongchenko, Stephen Lane, Dung-Yang Lee, Mathilde Kaper, Meredith McKean, Kathryn E. Beckermann, Samuel M. Rubinstein, Isabelle Rooney, Luna Musib, Nageshwar Budha, Jessie J. Hsu, Theodore S. Nowicki, Alexandre Avila, T Haas, Mäneka Puligandla, Sandra Lee, Shenying Fang, Jennifer A. Wargo, Jeffrey E. Gershenwald, Jeffrey E. Lee, Patrick Hwu, Paul B. Chapman, Jeffrey A. Sosman, Dirk Schadendorf, Jean‐Jacques Grob, Keith T. Flaherty, Dana Walker, Yibing Yan, Edward McKenna, Jeffrey J. Legos, Matteo S. Carlino, Antoni Ribas, John M. Kirkwood, Georgina V. Long, Douglas B. Johnson, Alexander M. Menzies, Michael A. Davies - The Lancet Oncology 2018 cited by 658

  21. A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor–Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention

    Authors: Spencer C. Wei, Wouter C. Meijers, Margaret L. Axelrod, Nana-Ama A.S. Anang, Elles M. Screever, Elizabeth C. Wescott, Douglas B. Johnson, Elizabeth M. Whitley, Lorenz Lehmann, Pierre‐Yves Courand, James J. Mancuso, Lauren E. Himmel, Bénédicte Lebrun-Vignes, Matthew J. Wleklinski, Björn C. Knollmann, Jayashree Srinivasan, Yu Li, Oluwatomisin T. Atolagbe, Xiayu Rao, Yang Zhao, Jing Wang, Lauren I. R. Ehrlich, Padmanee Sharma, Joe‐Elie Salem, Justin M. Balko, Javid J. Moslehi, James P. Allison - Cancer Discovery 2020 cited by 272

  22. A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti–PD-1 immunotherapy

    Authors: Balamayoora Theivanthiran, Kathy S. Evans, Nicholas C. DeVito, Michael P. Plebanek, Michael Sturdivant, Luke P. Wachsmuth, April K.S. Salama, Yubin Kang, David S. Hsu, Justin M. Balko, Douglas B. Johnson, Mark D. Starr, Andrew B. Nixon, Alisha Holtzhausen, Brent A. Hanks - Journal of Clinical Investigation 2020 cited by 250

  23. Cardiovascular toxicities associated with immune checkpoint inhibitors

    Authors: Jiun‐Ruey Hu, Roberta Florido, Evan J. Lipson, Jarushka Naidoo, Reza Ardehali, Carlo G. Tocchetti, Alexander R. Lyon, Robert F. Padera, Douglas B. Johnson, Javid J. Moslehi - Cardiovascular Research 2019 cited by 506

  24. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial

    Authors: Richard D. Carvajal, Marcus O. Butler, Alexander N. Shoushtari, Jessica C. Hassel, Alexandra P. Ikeguchi, Leonel F. Hernandez‐Aya, Paul Nathan, Omid Hamid, Josep M. Piulats, Matthew J. Rioth, Douglas B. Johnson, Jason J. Luke, Enrique Espinosa, Serge Leyvraz, Laura Collins, Howard Goodall, Koustubh Ranade, Chris Holland, Shaad E. Abdullah, Joseph J. Sacco, Takami Sato - Nature Medicine 2022 cited by 152